Platform Clinical Translation Award

Small Business Initiatives for Innovative tools and Technologies for Improving Outcomes for Maternal Health, NOT-EB-23-005 is sponsored by National Institutes of Health (NIH) - Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). This Notice of Special Interest (NOSI) seeks to advance maternal health research through small business innovation, focusing on projects for detecting, predicting, and/or monitoring conditions or disorders during pregnancy and/or the post-partum period that contribute to maternal morbidity and mortality. This includes clinical trials. The initiative is part of the 'Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)' initiative. Small businesses are encouraged to develop technologies, remote monitoring systems, clinical analytics platforms, and healthcare delivery solutions. While not explicitly mentioning GIS, the focus on 'clinical analytics platforms' and 'maternal risk prediction' suggests that GIS secondary data analysis could be a relevant tool in developing such innovative solutions.

To increase research capacity for NF, the NFRP is offering the NFRA. The intent of the NFRA is to provide a framework of intensive mentoring and iterative guidance with proposed research, national networking, collaborations, and a peer group of junior faculty (Scholars). The NFRP NFRA will bring together established NF investigators (one Director and one Deputy Director) and early-career independent investigators (Scholars) and their Career Guides to develop successful, highly productive NF scientists and clinicians that will conduct research with the aim of lessening the clinical impact of NF1, NF2, and schwannomatosis. The NFRA is a multi-institutional interactive virtual academy platform designed to offer support to NFRA Scholars with the goal to advance innovative, high impact NF research through a collaborative and career development environment.The functioning NFRA will consist of Scholars and their Career Guides (mentors) from different institutions, and an Academy Director and Deputy Director (see Figure 1 below). The Academy Director and Deputy Director will catalyze the growth and professional development of the Scholars in collaboration with their Career Guides, assess the progress of the Scholars, and facilitate communication and collaboration among all Academy members. The Career Guide is not required to be at the same institution as the Scholar; however, if the (primary) Career Guide is from a different institution, a secondary Career Guide at the Scholar’s institution is needed. The NFRA will afford Scholars opportunities to operate in a collegial, highly dynamic, and cutting-edge center to move early-career investigators towards positions as leaders in NF conducting impactful research.During this first phase of the academy, the NFRP is offering the FY24 NFRALA funding opportunity to solicit applications for an Academy Director and Deputy Director to lead the NFRA. The Academy Director and Deputy Director (referred to as Academy Leadership) must be established NF researchers and can be at different institutions. The Academy Leadership must demonstrate a strong record of mentoring and training early-career independent investigators, a commitment to leadership, the ability to articulate methods toward research collaborations, and the ability to objectively assess the progress of all Scholars in the NFRA. An objective of the NFRA leadership team is to establish the Academy structure in its first year and in subsequent years, conduct oversight of this activity. Other objectives will include execution of research that will engage NFRA FY25 Scholars (including subsequent-year Scholars), develop tools for Scholars to enable success, and provide opportunities to broaden their knowledge in NF disorders. The leadership team will identify and offer opportunities to network with other NFRP FY25 Early Investigator Research Award recipients (and subsequent year awardees) and NFRP FY25 New Investigator Award – Early-Stage Investigator (NIA – ESI) Award recipients (and subsequent year awardees). In the second stage of the academy, the NFRP anticipates release of funding opportunities for the Scholars who will conduct their research under the guidance of the NFRA leadership team. Funding Opportunity Number: HT942524NFRPNFRALA. Assistance Listing: 12.420. Funding Instrument: CA,G. Category: ST. Award Amount: $1.5M total program funding.

IA Resilience call reinforcing Europe's strenght in health is sponsored by European Commission — Horizon Europe. Expected Outcome: the proposals under this call are expected to address one or more of the following subjects : • Enhanced personalized monitoring, care and treatments, focusing on the development of highly customized healthcare solutions, including the required research and diagnostic tools, tailored to individual needs, covering various scenarios such as chronic disease management, physiotherapy, precision diagnosis, personalized medicine/treatment, pre- and postoperative care, and daily assistance in homes and common spaces. It also targets effective management of chronic diseases and elderly care through personalized monitoring and interventions facilitated by advanced sensor technologies and edge-to-cloud solutions. This includes the development and integration of solutions for Hospitalization at Home, enabling patients to receive complex, remotely supervised care using intelligent medical devices capable of sensing, analysing, and transmitting real-time data. This requires a continuum, from in-hospital diagnostics to robust, long-term patient support at home via AI-driven care pathways and hospitalization at home. • Prevention and treatment of diseases, allowing the improved scientific understanding, early detection and proactive prevention of diseases through scientific research, continuous monitoring, predictive analytics, and timely alerts, possibly powered by AI algorithms. This preventive approach enables early intervention and significantly reduces risks associated with many illnesses such as viral infections (e.g. epi- and pan demics), cardiovascular diseases, diabetes complications affecting the health of the young and old. • Efficient, scalable, and cost-effective healthcare, demonstrating how ECS-based technologies can streamline clinical workflows, reduce administrative burdens, and improve resource allocation in healthcare systems. This includes automation and intelligent operations management across clinical, diagnostic, and homecare settings, ultimately improving cost-effectiveness and scalability. • Secure and compliant healthcare continuum, including solutions that ensure robust data protection and regulatory compliance (e.g. GDPR), particularly in handling sensitive health data. Projects should adopt privacy-by-design principles and implement secure data handling architectures using localized edge computing, encryption, authentication, and anonymization strategies within both clinical and assisted living environments. • Seamless interoperability across devices, systems, and platforms, addressing the integration of heterogeneous systems across the edge-to-cloud continuum. Solutions should rely on open standards and modular architectures to ensure interoperability, flexibility, and adaptability across various healthcare settings and use cases, fostering a unified European health-tech ecosystem. Programme areas: Horizon Europe (HORIZON), Global Challenges and European Industrial Competitiveness, Digital, Industry and Space